‘With the takeover by our main shareholder, we now have the necessary planning security for the next stage of our company’s development,’ said ADVITOS Managing Director Dr Claus Jessen. The takeover is part of the insolvency plan that the management had developed with the support of the law firm JOBE. The creditors unanimously approved the plan in January.

ADVITOS launched the second generation of its ‘ADVOS multi’ therapy system on the market in December. This is a multi-organ support device for the kidneys, liver and lungs, which also enables the pH value to be adjusted for acidosis therapy and is used in intensive care medicine. The market launch will be accompanied by clinical studies to scientifically prove the superior efficacy of the new ADVOS therapy compared to conventional therapies. Since the beginning of the year, the therapy has been listed in the OPS catalogue, on the basis of which the clinics can now negotiate an additional fee with the health insurance companies for acidosis compensation.

The main shareholder wanted and wants to continue to support and finance this step and the company as a whole. However, some institutional investors among the shareholders did not want to participate in the further financing, but at the same time did not want to waive their own privileges. As part of the self-administration process, the shareholder structure has now been streamlined and reorganised. ‘Not only are we now solidly financed for the next steps, but we can also facilitate the entry of new investors,’ said Jessen.

The Managing Director thanked the employees, customers and suppliers for their support over the past few months. ‘Our employees have ensured that there have been no restrictions in production, delivery and service during the self-administration period, and our customers and suppliers have continued to place their trust in us and work with us as normal,’ said Jessen. ‘The collaboration with the insolvency administrator Dr Christian Gerloff from the law firm Gerloff Liebler Rechtsanwälte was also very targeted and professional.’

ADVITOS was founded in 2004 and has developed the so-called ‘ADVOS therapy’ (ADVanced Organ Support). This is the world’s first procedure for combined multi-organ support of the kidneys, liver and lungs as well as the regulation of the acid-base balance. As with classic dialysis, the patient’s blood is purified and processed outside the body. While only one organ – the kidney – is bypassed during dialysis, ADVOS therapy can take over the function of three organs simultaneously and regulate the pH value in the blood. The system is used in intensive care medicine to treat multiple organ failure – the most common cause of death in intensive care patients.

The therapy was certified and approved in Europe in 2013, and ADVITOS received MDR certification in February 2024. ADVITOS markets the ADVOS multi therapy system as a product. The device is successfully in clinical use at over 20 clinics in Germany and Austria. It increases the survival rate of intensive care patients by over 30 per cent. According to current plans, the company expects to become profitable in 2027.